A bivalent aptamer and terminus-free siRNA junction nanostructure for targeted gene silencing in cancer cells

Yang, Fang; Li, Shunmei; Yuan, Ruo; Xiang, Yun

doi:10.1039/d2tb01414a

Cited by 4 publications

(2 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Camorani S et al [27] coupled aptamers with siRNA targeting programmed cell death ligand 1 (PD-L1) to achieve effective gene silencing in triple-negative breast cancer. Fang Yang et al [28] developed a self-assembled structure of bivalent aptamer and terminal-free siRNA, which was easy to prepare and effective in inducing apoptosis. The coupling of nucleic acid aptamer and siRNA shows potential in the field of tumor-targeted therapy.…”

Section: Discussionmentioning

confidence: 99%

Regulating Oncogenic lncRNA VPS9D1-AS1 with Cholesterol-Modified siRNA for Esophageal Squamous Cell Carcinoma Therapy

Mu,

Wang,

Cai

et al. 2023

JCTR

View full text Add to dashboard Cite

Esophageal carcinoma is the tenth most common cancer in the world. long non-coding RNA (lncRNA) is a type of RNA molecule that has no or limited coding ability. Many studies have found that it plays an important role in the occurrence and development of tumors. This article aims to investigate the expression and clinical significance of lncRNA VPS9D1-AS1 in patients with esophageal squamous cell carcinoma (ESCC). Additionally, it aims to examine the effects of targeted silencing of VPS9D1-AS1 on the growth and migration of ESCC cells in vivo and in vitro, and to explore the mechanism of action. This study compared the expression difference of lncRNA VPS9D1-AS1 in ESCC tissues and normal tissues through TCGA and UCSC databases, and analyzed the correlation between VPS9D1-AS1 expression and the prognosis of ESCC patients; clinical samples from ESCC patients were collected and qRT-PCR (Fluorescent quantitative polymerase chain reaction) was used to detect the relative expression of VPS9D1-AS1 and analyze the correlation between the expression of VPS9D1-AS1 and the onset and development of ESCC. Specific small interfering RNA was used to knock down the expression of VPS9D1-AS1 in ESCC cells, and the effect of VPS9D1-AS1 on the proliferation and migration of esophageal squamous cell carcinoma cells was detected by CCK-8 and Transwell assays. A subcutaneous transplantation tumor model of ESCC cells was established, and cholesterol-modified si-VPS9D1-AS1 was injected around the tumor to detect the impact of VPS9D1-AS1 on ESCC tumor growth in vivo. Western blot was used to detect the expression of apoptosis-related proteins in the tumor tissues of mice in each group. Finally, it was found that lncRNA VPS9D1-AS1 was highly expressed in ESCC tissues and significantly correlated with the prognosis of ESCC patients. Knocking down VPS9D1-AS1 regulates the proliferation, migration, and apoptosis of ESCC cells, and inhibits the growth of transplanted tumors in vivo, indicating it is a potential diagnostic and therapeutic target for esophageal squamous cell carcinoma.

show abstract

Section: Discussionmentioning

confidence: 99%

Regulating Oncogenic lncRNA VPS9D1-AS1 with Cholesterol-Modified siRNA for Esophageal Squamous Cell Carcinoma Therapy

Mu,

Wang,

Cai

et al. 2023

JCTR

View full text Add to dashboard Cite

show abstract

“…On this basis, numerous related methods based on DNA nanotechnology have been reported over the past years. [125][126][127][128] For instance, Shin's group designed diversified rectangular and tubular DNA nanostructures of different dimensions and shapes by the modularized DNA brick approach, which enabled high-efficiency transport of siRNA targeting the Bcl2 protein with anti-apoptosis function. 125 The experimental results showed that DNA nanoparticles had high endocytosis efficiency; the loaded siBcl2 could down-regulate the Bcl2 expression by about 90% and silence Bcl2 mRNA by about 70%, subsequently inhibiting cell growth.…”

Section: Therapeutic Nucleic Acid Delivery and Disease Treatmentmentioning

confidence: 99%

DNA nanotechnology-based nucleic acid delivery systems for bioimaging and disease treatment

Sun,

Ren,

Zhu

et al. 2024

Analyst

View full text Add to dashboard Cite

show abstract

An anti-GD2 aptamer-based bifunctional spherical nucleic acid nanoplatform for synergistic therapy targeting MDM2 for retinoblastoma

Wang,

Zhao,

Yao

et al. 2024

Biomedicine & Pharmacotherapy

View full text Add to dashboard Cite

A bivalent aptamer and terminus-free siRNA junction nanostructure for targeted gene silencing in cancer cells

Abstract: Small interfering RNA (siRNA) has increasingly evolved as a potent therapeutic solution for several pathological conditions including cancers via post-transcriptional oncogene suppression in cellular pathways. And, the key for siRNA-based...

Cited by 4 publications

References 39 publications

Regulating Oncogenic lncRNA VPS9D1-AS1 with Cholesterol-Modified siRNA for Esophageal Squamous Cell Carcinoma Therapy

Regulating Oncogenic lncRNA VPS9D1-AS1 with Cholesterol-Modified siRNA for Esophageal Squamous Cell Carcinoma Therapy

DNA nanotechnology-based nucleic acid delivery systems for bioimaging and disease treatment

An anti-GD2 aptamer-based bifunctional spherical nucleic acid nanoplatform for synergistic therapy targeting MDM2 for retinoblastoma

Contact Info

Product

Resources

About